What Was Approved?
On June 17, 2026, the U.S. Food and Drug Administration approved Utebzi (tebipenem pivoxil) for adults with complicated urinary tract infections, including pyelonephritis, caused by certain susceptible bacteria.
The approval is specifically for adults who have limited or no alternative oral treatment options.
What Is Utebzi?
Utebzi is an oral penem antibacterial medicine.
It belongs to the broader beta-lactam family and provides an oral treatment option for certain serious urinary tract infections that may otherwise be difficult to treat with available oral antibiotics.
Which Bacteria Are Included in the FDA-Approved Indication?
The FDA-approved labeling includes susceptible strains of:
- Escherichia coli
- Klebsiella pneumoniae
- Enterobacter cloacae complex
- Klebsiella oxytoca
- Enterococcus faecalis
Treatment should be guided by the suspected or confirmed bacterial cause and other clinical factors.
How Is Utebzi Taken?
For adults with normal or mildly reduced kidney function, the recommended dose is:
600 mg by mouth every 6 hours for 7 to 10 days.
The dose must be reduced in certain patients with impaired kidney function.
Utebzi may be taken with or without food.
Why Is Antibiotic Stewardship Important?
Utebzi should not be used for viral illnesses or unnecessary infections.
The FDA labeling states that it should be used only when an infection is proven or strongly suspected to be caused by bacteria, in order to help reduce the development of drug-resistant bacteria.
What Are Important Safety Considerations?
As with other beta-lactam antibiotics, serious allergic reactions can occur.
The prescribing information also includes warnings related to antibiotic-associated diarrhea, including Clostridioides difficile-associated diarrhea, and other potential adverse effects.
Because dosing depends partly on kidney function, renal function should also be considered before and during treatment.
Are Drug Interactions Possible?
Yes.
For example, probenecid can increase tebipenem exposure.
The FDA labeling recommends closer monitoring for adverse reactions if Utebzi must be used with certain OAT1 or OAT3 inhibitors.
Why Is This Approval Important?
Before Utebzi, carbapenem-class therapy generally required intravenous administration in the United States.
Utebzi provides the first FDA-approved oral carbapenem-related option for certain adults with complicated urinary tract infections who have limited oral alternatives.
Bottom Line
Utebzi (tebipenem pivoxil) is a newly FDA-approved oral antibacterial treatment for certain complicated urinary tract infections, including pyelonephritis, in adults with limited or no alternative oral options.
Because inappropriate antibiotic use can contribute to resistance, treatment should be based on the likely or confirmed bacterial cause and guided by a healthcare professional.
Sources
- U.S. Food and Drug Administration (FDA) — FDA Approves First Oral Carbapenem Therapy for Complicated Urinary Tract Infections, June 17, 2026.
- U.S. Food and Drug Administration (FDA) — Utebzi (tebipenem pivoxil) Prescribing Information, June 2026.
- U.S. Food and Drug Administration (FDA) — Novel Drug Approvals for 2026.